Shares of Cardiovascular Systems, Inc. (NASDAQ:CSII) have been given an average recommendation of “Hold” by the nine research firms that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $34.40.
A number of brokerages recently issued reports on CSII. Zacks Investment Research lowered shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. BidaskClub downgraded shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $37.00 price target (up previously from $32.00) on shares of Cardiovascular Systems in a research note on Friday, July 14th. Bank of America Corporation downgraded shares of Cardiovascular Systems from a “neutral” rating to an “underperform” rating in a research note on Wednesday, June 21st. Finally, TheStreet raised shares of Cardiovascular Systems from a “d” rating to a “c-” rating in a research note on Thursday, May 4th.
ILLEGAL ACTIVITY WARNING: This story was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.com-unik.info/2017/08/12/cardiovascular-systems-inc-csii-receives-34-40-consensus-pt-from-analysts-updated-updated-updated.html.
Cardiovascular Systems (CSII) opened at 30.57 on Friday. Cardiovascular Systems has a 1-year low of $21.29 and a 1-year high of $33.11. The stock has a 50 day moving average price of $31.68 and a 200 day moving average price of $29.58. The stock’s market cap is $1.00 billion.
Cardiovascular Systems (NASDAQ:CSII) last released its quarterly earnings results on Wednesday, August 2nd. The medical device company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.07. Cardiovascular Systems had a negative net margin of 0.87% and a positive return on equity of 0.89%. The business had revenue of $52.90 million for the quarter, compared to analyst estimates of $51.98 million. During the same period in the prior year, the business earned ($0.15) earnings per share. The company’s quarterly revenue was up 9.1% on a year-over-year basis. On average, analysts predict that Cardiovascular Systems will post $0.04 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CSII. BNP Paribas Arbitrage SA boosted its stake in shares of Cardiovascular Systems by 160.7% in the second quarter. BNP Paribas Arbitrage SA now owns 5,135 shares of the medical device company’s stock worth $166,000 after buying an additional 3,165 shares during the last quarter. Quantbot Technologies LP boosted its position in Cardiovascular Systems by 142.3% in the first quarter. Quantbot Technologies LP now owns 5,323 shares of the medical device company’s stock valued at $150,000 after buying an additional 3,126 shares during the last quarter. Winslow Evans & Crocker Inc. bought a new position in Cardiovascular Systems during the first quarter valued at approximately $153,000. Old Mutual Global Investors UK Ltd. bought a new position in Cardiovascular Systems during the first quarter valued at approximately $163,000. Finally, Clinton Group Inc. bought a new position in Cardiovascular Systems during the first quarter valued at approximately $212,000. 75.15% of the stock is currently owned by institutional investors and hedge funds.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
What are top analysts saying about Cardiovascular Systems Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cardiovascular Systems Inc. and related companies.